文献速递临床试验与 GCP流行病学与生物统计

外周灌注靶向复苏对脓毒性休克28天死亡率的影响:ANDROMEDA-SHOCK随机临床试验

Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

ANDROMEDA-SHOCK多中心随机试验纳入424例脓毒性休克患者,比较以毛细血管再充盈时间正常化为目标与以乳酸水平正常化或每2小时下降>20%为目标的复苏策略。

要点

  • 外周灌注靶向复苏未显著降低脓毒性休克28天全因死亡率。
  • 外周灌注组72小时器官功能障碍(SOFA评分)显著低于乳酸组。
  • 两组其他6项次要结局无显著差异,无方案相关严重不良反应。

核心结论

  • 在脓毒性休克患者中,以毛细血管再充盈时间正常化为目标的复苏策略与以血清乳酸水平为目标的策略相比,未降低28天全因死亡率。

研究设计与样本

  • 多中心随机临床试验,在5个国家28个重症监护病房进行,2017年3月至2018年3月纳入424例脓毒性休克患者,最后随访日期为2018年6月12日。

主要发现

  • 其他6项次要结局无显著差异,未确认方案相关严重不良反应。

关键数值与推荐

  • 外周灌注组目标为毛细血管再充盈时间正常化(n=212),乳酸组目标为乳酸正常化或每2小时下降>20%(n=212),干预期8小时。
  • 主要结局为28天全因死亡率;次要结局包括72小时SOFA评分、90天内死亡、28天内无机械通气/肾脏替代/血管加压药天数、ICU和住院时长。

临床怎么用

  • 对于早期脓毒性休克成人患者,外周灌注靶向复苏可作为乳酸靶向复苏的替代策略,但需注意其未显著降低28天死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Abnormal peripheral perfusion after septic shock resuscitation has been associated with organ dysfunction and mortality. The potential role of the clinical assessment of peripheral perfusion as a target during resuscitation in early septic shock has not been established. OBJECTIVE: To determine if a peripheral perfusion-targeted resuscitation during early septic shock in adults is more effective than a lactate level-targeted resuscitation for reducing mortality. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized trial conducted at 28 intensive care units in 5 countries. Four-hundred twenty-four patients with septic shock were included between March 2017 and March 2018. The last date of follow-up was June 12, 2018. INTERVENTIONS: Patients were randomized to a step-by-step resuscitation protocol aimed at either normalizing capillary refill time (n = 212) or normalizing or decreasing lactate levels at rates greater than 20% per 2 hours (n = 212), during an 8-hour intervention period. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality at 28 days. Secondary outcomes were organ dysfunction at 72 hours after randomization, as assessed by Sequential Organ Failure Assessment (SOFA) score (range, 0 [best] to 24 [worst]); death within 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days within 28 days; intensive care unit and hospital length of stay. RESULTS: Among 424 patients randomized (mean age, 63 years; 226 [53%] women), 416 (98%) completed the trial. By day 28, 74 patients (34.9%) in the peripheral perfusion group and 92 patients (43.4%) in the lactate group had died (hazard ratio, 0.75 [95% CI, 0.55 to 1.02]; P = .06; risk difference, -8.5% [95% CI, -18.2% to 1.2%]). Peripheral perfusion-targeted resuscitation was associated with less organ dysfunction at 72 hours (mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, -1.00 [95% CI, -1.97 to -0.02]; P = .045). There were no significant differences in the other 6 secondary outcomes. No protocol-related serious adverse reactions were confirmed. CONCLUSIONS AND RELEVANCE: Among patients with septic shock, a resuscitation strategy targeting normalization of capillary refill time, compared with a strategy targeting serum lactate levels, did not reduce all-cause 28-day mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03078712.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. JAMA. 2019. PMID: 30772908. doi:10.1001/jama.2019.0071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。